Latest News

Print

Cancer association recognizes three scientists for advancing research

Post Date:June 30, 2020 9:00 AM
UCLA cancer researchers (left to right) Tracy Daniels-Wells, Willy Hugo and Cristina Puig Saus

Three researchers from the UCLA Jonsson Comprehensive Cancer Center are part of the newest class of the American Association for Cancer Research grant and award recipients for dedicating their careers to advancing the detection, prevention, and treatment of cancer. The awards were announced during second part of the virtual AACR Annual Meeting.

The 2020 award recipients from UCLA were:

Cristina Puig Saus, PhD, adjunct assistant professor of medicine and hematology/oncology, received the NextGen Star Award that recognizes early-career investigators for transformative cancer research. Puig Saus was honored for her efforts in making immunotherapies work better for more people. She is currently studying how T-cells respond to mutations in tumors after immune checkpoint blockade treatment. Understanding the T cell responses induced after therapy in patients with or without response will inform the design of personalized adoptive T cell therapies.

Tracy Daniels-Wells, PhD, adjunct assistant professor in the department of surgery and division of surgical oncology, received the AACR Minority and Minority-serving Institution Faculty Scholar in Cancer Research Awards. This award helps increase the scientific knowledge base of minority faculty members and faculty members at minority-serving institutions. It encourages them and their students to pursue careers in cancer research. Daniels-Wells is a member of the Nottawaseppi Huron Band of the Potawatomi. Her research focuses on the development of novel antibody-based therapeutics that can either directly eliminate cancer cells or can “teach” the immune system to fight cancer.

Willy Hugo, PhD, adjunct assistant professor of dermatology at the David Geffen School of Medicine at UCLA, was recognized with the AACR-Bayer Innovation & Discovery grant. This award goes to researchers providing new treatment options for cancers with a high unmet medical need that encourages collaboration between academic groups and the pharmaceutical industry to help translate ideas from basic research to novel drugs. Hugo is studying the role of the interaction between tumor cells and the immune/stromal cells in the tumor microenvironment and how such interaction influences the development of resistance toward targeted- and immunotherapies in cancer.

Return to full list >>